Using the C. elegans ALS model, the Parker group screened more than 4000 FDA approved compounds and identified methylene blue, an aggregation inhibitor of the phenothiazine class, as a potent suppressor of mutant TDP-43 and FUS-induced neurotoxicity (Vaccaro et al., 2012b; Vaccaro et al., 2013; Therrien and Parker, 2014). Here, FUS is linked to amyotrophic lateral sclerosis.